0001213900-26-101304.txt : 20260918 0001213900-26-101304.hdr.sgml : 20260918 20260918131731 ACCESSION NUMBER: 0001213900-26-101304 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: Rule 506(b) provides a "safer harbor" for a private offering FILED AS OF DATE: 20260918 DATE AS OF CHANGE: 20260918 EFFECTIVENESS DATE: 20260918 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GevRx Nutraceuticals, Inc. CENTRAL INDEX KEY: 0002156105 ORGANIZATION NAME: EIN: 413736211 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-598108 FILM NUMBER: 261390186 BUSINESS ADDRESS: STREET 1: 20 MARBLE LOOP STREET 2: SUITE 2A CITY: STATEN ISLAND STATE: NY ZIP: 10309 BUSINESS PHONE: 9179399424 MAIL ADDRESS: STREET 1: 20 MARBLE LOOP STREET 2: SUITE 2A CITY: STATEN ISLAND STATE: NY ZIP: 10309 D 1 primary_doc.xml X0708 D LIVE 0002156105 GevRx Nutraceuticals, Inc. 20 MARBLE LOOP SUITE 2A STATEN ISLAND NY NEW YORK 10309 (917) 939-9424 DELAWARE None None Corporation true 2026 James Thomas Christopher 20 Marble Loop Suite 2A Staten Island NY NEW YORK 10309 Executive Officer Director President, Secretary and Treasurer Douglas Spiel, M.D. 20 Marble Loop Suite 2A Staten Island NY NEW YORK 10309 Executive Officer Director Chief Executive Officer and Chief Medical Director Mary Stephen Esposito 20 Marble Loop Suite 2A Staten Island NY NEW YORK 10309 Director Dylan Tyler Spiel 20 Marble Loop Suite 2A Staten Island NY NEW YORK 10309 Executive Officer Vice President Michael J. Betley, Ph.D. 20 Marble Loop Suite 2A Staten Island NY NEW YORK 10309 Executive Officer Chief Scientific Officer Biotechnology Decline to Disclose 06b false 2026-09-11 false true false 0 3000000 300000 2700000 The total offering amount reflects the gross proceeds to be received assuming sale of 300,000 shares of common stock, par value $0.001 per share, of the Company, at a price of $10.00 per share. false 1 0 0 0 While no offering proceeds are set aside for payments to the named officers or directors, it is possible that some proceeds to be used as working capital will be used indirectly for paying salaries to employees including executive officers. false GevRx Nutraceuticals, Inc. /s/ James Christopher James Christopher President, Secretary and Treasurer 2026-09-18